drugset / Trial / NCT01762202

Assessment of Efficacy and Safety of Front-line Fludarabine, Cyclophoshamide and Ofatumumab Chemoimmunotherapy in Young Patients With Chronic Lymphocytic Leukemia.

NCT01762202

Phase 2 Completed 80 enrolled GIMEMA Foundation
NaSingle-groupOpen-labelTreatment

Summary

Assessment of safety and efficacy of with fludarabine and cyclophosphamide (FC) combined with ofatumumab (FCO2) in previously untreated "young" patients with Chronic Lymphocytic Leukemia (CLL).

Timeline

Start
2013-11-05
Primary completion
2015-11
Completion
2018-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified
Subject Fludarabine Small molecule
Subject Ofatumumab Monoclonal antibody

Indications